{"protocolSection": {"identificationModule": {"nctId": "NCT01816776", "orgStudyIdInfo": {"id": "Respicardia CR-1005"}, "organization": {"fullName": "Respicardia, Inc.", "class": "INDUSTRY"}, "briefTitle": "Respicardia, Inc. Pivotal Trial of the remed\u0113 System", "officialTitle": "A Randomized Trial Evaluating the Safety and Effectiveness of the remed\u0113\u00ae System in Patients With Central Sleep Apnea"}, "statusModule": {"statusVerifiedDate": "2018-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2013-03"}, "primaryCompletionDateStruct": {"date": "2016-09-10", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-11-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2013-03-19", "studyFirstSubmitQcDate": "2013-03-21", "studyFirstPostDateStruct": {"date": "2013-03-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-06-13", "resultsFirstSubmitQcDate": "2017-06-13", "resultsFirstPostDateStruct": {"date": "2017-07-11", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-05-31", "lastUpdatePostDateStruct": {"date": "2018-06-29", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Respicardia, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The primary purpose of this prospective, multicenter, randomized trial is to evaluate the safety and effectiveness of therapy delivered by the remed\u0113\u00ae system in subjects with moderate to severe central sleep apnea and optimal medical management, compared to outcomes in randomized control subjects receiving optimal medical management and implanted but inactive remed\u0113\u00ae systems."}, "conditionsModule": {"conditions": ["Sleep Apnea, Central", "Sleep Disordered Breathing", "Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 151, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Treatment Group", "type": "EXPERIMENTAL", "description": "Subjects implanted with the remed\u0113 system device and randomized to the Treatment group will receive optimal medical therapy and have the remed\u0113 system initiated to deliver transvenous stimulation of the phrenic nerve at the Therapy Initiation Visit (1 month post device implant).", "interventionNames": ["Device: Treatment Group (transvenous stimulation of the phrenic nerve)"]}, {"label": "Control group", "type": "OTHER", "description": "Subjects implanted with the remed\u0113 system device and randomized to the Control group will receive optimal medical therapy through the 6-month Post-Therapy Initiation Visit. Control group subjects will have the remed\u0113 system initiated to deliver transvenous stimulation of the phrenic nerve at the 6-month Post-Therapy Initiation Visit (7 months post device implant).", "interventionNames": ["Device: Control Group (Optimal Medical Therapy)"]}], "interventions": [{"type": "DEVICE", "name": "Treatment Group (transvenous stimulation of the phrenic nerve)", "description": "device implant, optimal medical therapy and device initiation 1 month post implant.", "armGroupLabels": ["Treatment Group"], "otherNames": ["remed\u0113 System", "Transvenous stimulation of the phrenic nerve"]}, {"type": "DEVICE", "name": "Control Group (Optimal Medical Therapy)", "description": "device implant, optimal medical therapy and delayed device initiation (7 months post device implant)", "armGroupLabels": ["Control group"], "otherNames": ["Optimal Medical Therapy"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "The Proportion of Participants Experiencing a Reduction in Apnea-hypopnea Index (AHI)", "description": "Comparison of the proportion of subjects in the Treatment group achieving a 50% or greater reduction in AHI from baseline to 6 months compared to the Control group.", "timeFrame": "6 months"}, {"measure": "Freedom From Related Serious Adverse Events Within 12 Months", "description": "Freedom from serious adverse events (SAEs) associated with the implant procedure, the remede System, or the delivered therapy at 12 months post therapy initiation visit.", "timeFrame": "12 months"}], "secondaryOutcomes": [{"measure": "Central Apnea Index (CAI) Change From Baseline at 6 Months", "description": "Change in CAI = Month 6 index - Baseline index. The central apnea index is a measurement used to indicate the severity of central sleep apnea. It is represented by the number of central apnea events per hour of sleep.", "timeFrame": "6 months"}, {"measure": "Apnea-Hypopnea Index (AHI) Change From Baseline at 6 Months", "description": "Change in AHI = Month 6 index - Baseline index. The Apnea-Hypopnea Index is a measurement used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep.", "timeFrame": "6 months"}, {"measure": "Arousal Index (ArI) Change From Baseline at 6 Months", "description": "Change in ArI = Month 6 index - Baseline index. The Arousal Index is a measurement used to indicate the number of times per hour of sleep that sleep is disrupted.", "timeFrame": "6 months"}, {"measure": "Rapid Eye Movement (REM) Sleep Change From Baseline at 6 Months", "description": "Change in REM = Month 6 percentage - Baseline percentage. Rapid Eye Movement (REM) is a sleep stage. A higher percentage of sleep in REM is a measure of better sleep quality.", "timeFrame": "6 months"}, {"measure": "The Proportion of Participants Experiencing a Marked or Moderate Improvement in Patient Global Assessment at 6 Months", "description": "The proportion of subjects with a \"moderate\" or \"marked\" improvement in the Patient Global Assessment from baseline to the 6 month visit", "timeFrame": "6 months"}, {"measure": "Oxygen Desaturation Index 4% (ODI4) Change From Baseline at 6 Months", "description": "Change in ODI4 = Month 6 index - Baseline index. The Oxygen Desaturation Index 4% is a measurement of the number of times per hour of sleep that the blood's oxygen level drops \u22654%.", "timeFrame": "6 months"}, {"measure": "Epworth Sleepiness Scale (ESS) Change From Baseline at 6 Months", "description": "Change in ESS = Month 6 score - Baseline score. The ESS is an assessment to measure a subject's general level of daytime sleepiness. Scores can range from 0-24, with higher scores indicating higher level of daytime sleepiness.", "timeFrame": "6 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. At least 18 years of age\n2. Central Sleep apnea confirmed by core lab analysis of PSG with EEG within 40 days of scheduled implant:\n\n   * Apnea/Hypopnea Index (AHI) greater than or equal to 20;\n   * Central Apnea Index (CAI) at least 50% of all apneas, with at least 30 central apnea events;\n   * Oxygen Desaturation Index (OAI) less than or equal to 20% of the total AHI\n3. Medically stable for 30 days prior to all baseline testing (including PSG), i.e., no hospitalizations for illness, no breathing mask-based therapy, and on stable medications and therapies:\n\n   * Stable medications are defined as no changes during this period except for those within a pre-specified sliding scale medication regimen;\n   * If the subject has heart failure, the baseline testing (including PSG) should occur at least 6 months after initial diagnosis;\n   * If the subject has systolic heart failure, the baseline testing (including PSG) should occur after maximally titrating beta blockers, angiotensin converting enzyme inhibitors (ACE-I) and other medications indicated in the current guidelines (unless contraindicated or not considered medically necessary) and after receiving any indicated device therapy including devices for cardiac resynchronization therapy and/or primary prevention of sudden cardiac death;\n   * If subject has a hospitalization or physician visit requiring IV medication between the screening PSG and implant, the subject must be re-screened when stable\n4. Expected to tolerate study procedures in the opinion of the investigator, in particular:\n\n   * Ability to lie down long enough to insert the remede system without shortness of breath and able to tolerate instrumentation for the Polysomnogram/Polygram testing;\n   * Expected to tolerate therapy titration and the sensation of therapy, and communicate therapy experience.\n5. In the investigator's opinion, willing and able to comply with all study requirements\n6. Signed the Institutional Review Board/Medical Ethics Committee approved informed consent (HIPAA authorization in the U.S.)\n\nExclusion Criteria:\n\n1. Pacemaker dependent subjects without any physiologic escape rhythm\n2. Suspected inability to place catheter for delivery of stimulation lead (e.g. previously know coagulopathy, distorted anatomy, prior failed pectoral implant, etc.)\n3. Evidence of phrenic nerve palsy\n4. More than 2 previous open chest surgical procedures (e.g., CABG)\n5. Etiology of central sleep apnea known to be caused primarily by pain medication\n6. Documented history of psychosis or severe bipolar disorder\n7. Cerebrovascular accident (CVA) within 12 months of baseline testing\n8. History of idiopathic pulmonary hypertension, World Health Organization Class 1\n9. Limited pulmonary function with either forced expiratory volume (FEV) 1/forced vital capacity (FVC) less than 65% of predicted value or FVC less than 60% of predicted value\n10. Baseline oxygen saturation less than 92% while awake and on room air after 5 minutes of quiet rest\n11. Anticipated need for chronic oxygen therapy or breathing mask-based therapy for 6 months post therapy initiation visit\n12. Active infection or sepsis within 30 days of enrollment\n13. Currently on renal dialysis or creatinine level greater than 2.5 mg/dL or calculated creatinine clearance equal to or less than 30 ml/min using the Cockcroft-Gault equation\n14. Poor liver function with baseline aspartate transaminase (AST), alanine transaminase (ALT), and/or total bilirubin greater than 3 times the upper limit of normal (per lab normals at each site)\n15. Hemoglobin less than 8 gm/dL\n16. In subjects with heart failure, American College of Cardiology (ACC)/American Heart Association Heart (AHA) Stage D\n17. Within the 3 months prior to baseline testing, any of the following: uncorrected severe valvular stenosis, valve replacement or repair (percutaneous or surgical), myocardial infarction (MI), coronary artery bypass grafting (CABG) surgery, percutaneous coronary intervention (PCI), cardiac ablation, new cardiac resynchronization device or new pacemaker implant\n18. New implantable cardioverter defibrillator or any implantable device generator change-out within 30 days prior to baseline testing or anticipated within the first 6 months of enrollment\n19. Other anticipated surgery or invasive procedure expected to affect ability to perform testing at 6-month post-therapy initiation visit\n20. Unstable angina\n21. Allergy to or intolerant of contrast dye\n22. Pregnancy or of child bearing potential without a negative pregnancy test within 10 days prior to remede system implant\n23. Life expectancy or expected time to transplant or left ventricular assist device of less than 12 months\n24. Currently enrolled or planning to enroll in another study that may conflict with protocol requirements or confound subject results in this trial", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Maria Rosa Costanzo, M.D.", "affiliation": "Midwest Heart Specialists", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Keck Hospital of USC", "city": "Los Angeles", "state": "California", "zip": "90033", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "University of Florida - Jacksonville", "city": "Jacksonville", "state": "Florida", "zip": "32209", "country": "United States", "geoPoint": {"lat": 30.33218, "lon": -81.65565}}, {"facility": "Advocate Medical Group", "city": "Downers Grove", "state": "Illinois", "zip": "60566", "country": "United States", "geoPoint": {"lat": 41.80892, "lon": -88.01117}}, {"facility": "Edward Hospital-Advocate Medical Group", "city": "Naperville", "state": "Illinois", "zip": "60566", "country": "United States", "geoPoint": {"lat": 41.78586, "lon": -88.14729}}, {"facility": "University of Maryland, Baltimore", "city": "Baltimore", "state": "Maryland", "zip": "21201", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Johns Hopkins Bayview Medical Center", "city": "Baltimore", "state": "Maryland", "zip": "21287", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Detroit Clinical Research Center", "city": "Farmington Hills", "state": "Michigan", "zip": "48334", "country": "United States", "geoPoint": {"lat": 42.48531, "lon": -83.37716}}, {"facility": "Spectrum Health", "city": "Grand Rapids", "state": "Michigan", "zip": "49525", "country": "United States", "geoPoint": {"lat": 42.96336, "lon": -85.66809}}, {"facility": "United Heart and Vascular (Allina)", "city": "Saint Paul", "state": "Minnesota", "zip": "55102", "country": "United States", "geoPoint": {"lat": 44.94441, "lon": -93.09327}}, {"facility": "Mid America Heart Institute", "city": "Kansas City", "state": "Missouri", "zip": "64111", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Washington University", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Bryan Heart", "city": "Lincoln", "state": "Nebraska", "zip": "68506", "country": "United States", "geoPoint": {"lat": 40.8, "lon": -96.66696}}, {"facility": "Cooper Health System", "city": "Cherry Hill", "state": "New Jersey", "zip": "08034", "country": "United States", "geoPoint": {"lat": 39.93484, "lon": -75.03073}}, {"facility": "Novant Medical Group, Inc. Presbyterian Sleep Health Charlotte", "city": "Charlotte", "state": "North Carolina", "zip": "28204", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Forsyth Medical Center - Novant", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "The Lindner Center for Research and Education at Christ Hospital", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Ohio State University", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "Lancaster General Hospital", "city": "Lancaster", "state": "Pennsylvania", "zip": "17603", "country": "United States", "geoPoint": {"lat": 40.03788, "lon": -76.30551}}, {"facility": "Hospital of University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Stern Cardiovascular", "city": "Memphis", "state": "Tennessee", "zip": "38138", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Methodist Healthcare System", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Virginia Commonwealth University", "city": "Richmond", "state": "Virginia", "zip": "23219", "country": "United States", "geoPoint": {"lat": 37.55376, "lon": -77.46026}}, {"facility": "Marshfield Clinic", "city": "Marshfield", "state": "Wisconsin", "zip": "54449", "country": "United States", "geoPoint": {"lat": 44.66885, "lon": -90.1718}}, {"facility": "Bad Oeynhausen- Heart & Diabetes Center", "city": "Bad Oeynhausen", "country": "Germany", "geoPoint": {"lat": 52.20699, "lon": 8.80365}}, {"facility": "Charite Medical School, Campus Virchow-Klinikum", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Bernau-Herzzentruym Brandenburg", "city": "Bernau", "country": "Germany", "geoPoint": {"lat": 52.67982, "lon": 13.58708}}, {"facility": "Bielefeld-Klinikun", "city": "Bielefeld", "country": "Germany", "geoPoint": {"lat": 52.03333, "lon": 8.53333}}, {"facility": "Hamburg: Universitares Herzzentrum", "city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Ambulantes Herzzentrum-Kassel", "city": "Kassel", "country": "Germany", "geoPoint": {"lat": 51.31667, "lon": 9.5}}, {"facility": "Fourth Military Hospital", "city": "Wroclaw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}]}, "referencesModule": {"references": [{"pmid": "33953626", "type": "DERIVED", "citation": "Costanzo MR, Javaheri S, Ponikowski P, Oldenburg O, Augostini R, Goldberg LR, Stellbrink C, Fox H, Schwartz AR, Gupta S, McKane S, Meyer TE, Abraham WT; remede(R)System Pivotal Trial Study Group. Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes. Nat Sci Sleep. 2021 Apr 29;13:515-526. doi: 10.2147/NSS.S300713. eCollection 2021."}, {"pmid": "33745107", "type": "DERIVED", "citation": "Schwartz AR, Goldberg LR, McKane S, Morgenthaler TI. Transvenous phrenic nerve stimulation improves central sleep apnea, sleep quality, and quality of life regardless of prior positive airway pressure treatment. Sleep Breath. 2021 Dec;25(4):2053-2063. doi: 10.1007/s11325-021-02335-x. Epub 2021 Mar 20."}, {"pmid": "32946372", "type": "DERIVED", "citation": "Javaheri S, McKane S. Transvenous phrenic nerve stimulation to treat idiopathic central sleep apnea. J Clin Sleep Med. 2020 Dec 15;16(12):2099-2107. doi: 10.5664/jcsm.8802."}, {"pmid": "32803641", "type": "DERIVED", "citation": "Costanzo MR. Central Sleep Apnea in Patients with Heart Failure-How to Screen, How to Treat. Curr Heart Fail Rep. 2020 Oct;17(5):277-287. doi: 10.1007/s11897-020-00472-0."}, {"pmid": "32789619", "type": "DERIVED", "citation": "Oldenburg O, Costanzo MR, Germany R, McKane S, Meyer TE, Fox H. Improving Nocturnal Hypoxemic Burden with Transvenous Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea. J Cardiovasc Transl Res. 2021 Apr;14(2):377-385. doi: 10.1007/s12265-020-10061-0. Epub 2020 Aug 12. Erratum In: J Cardiovasc Transl Res. 2022 Jun;15(3):687. doi: 10.1007/s12265-021-10179-9."}, {"pmid": "31634407", "type": "DERIVED", "citation": "Fox H, Oldenburg O, Javaheri S, Ponikowski P, Augostini R, Goldberg LR, Stellbrink C, Mckane S, Meyer TE, Abraham WT, Costanzo MR. Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. Sleep. 2019 Oct 21;42(11):zsz158. doi: 10.1093/sleep/zsz158."}, {"pmid": "27598679", "type": "DERIVED", "citation": "Costanzo MR, Ponikowski P, Javaheri S, Augostini R, Goldberg L, Holcomb R, Kao A, Khayat RN, Oldenburg O, Stellbrink C, Abraham WT; remede System Pivotal Trial Study Group. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. Lancet. 2016 Sep 3;388(10048):974-82. doi: 10.1016/S0140-6736(16)30961-8. Epub 2016 Sep 1."}, {"pmid": "26432647", "type": "DERIVED", "citation": "Costanzo MR, Augostini R, Goldberg LR, Ponikowski P, Stellbrink C, Javaheri S. Design of the remede System Pivotal Trial: A Prospective, Randomized Study in the Use of Respiratory Rhythm Management to Treat Central Sleep Apnea. J Card Fail. 2015 Nov;21(11):892-902. doi: 10.1016/j.cardfail.2015.08.344."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Treatment Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy and remed\u0113 System therapy."}, {"id": "FG001", "title": "Control Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy alone (remed\u0113 System inactive through 6 months)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "Randomized", "achievements": [{"groupId": "FG000", "numSubjects": "73"}, {"groupId": "FG001", "numSubjects": "78"}]}, {"type": "6 Month Primary Effectiveness Assessed", "achievements": [{"groupId": "FG000", "numSubjects": "68"}, {"groupId": "FG001", "numSubjects": "73"}]}, {"type": "COMPLETED", "comment": "Primary safety assessed through 12 months", "achievements": [{"groupId": "FG000", "numSubjects": "60"}, {"groupId": "FG001", "numSubjects": "70"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "8"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Intent-to-treat", "groups": [{"id": "BG000", "title": "Treatment Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy and remed\u0113 System therapy."}, {"id": "BG001", "title": "Control Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy alone (remed\u0113 System inactive through 6 months)."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "65", "spread": "12"}, {"groupId": "BG001", "value": "65", "spread": "13"}, {"groupId": "BG002", "value": "65", "spread": "13"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "16"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "63"}, {"groupId": "BG001", "value": "72"}, {"groupId": "BG002", "value": "135"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "5"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "72"}, {"groupId": "BG001", "value": "74"}, {"groupId": "BG002", "value": "146"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "6"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "70"}, {"groupId": "BG001", "value": "74"}, {"groupId": "BG002", "value": "144"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "99"}]}]}, {"title": "Poland", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "21"}]}]}, {"title": "Germany", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "14"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "31"}]}]}]}, {"title": "Apnea-Hypopnea Index (AHI)", "description": "The number of apneas and hypopneas per hour of sleep.\n\nAn apnea is defined by 3 characteristics:\n\n1. There is a drop in the peak thermal sensor excursion or alternate nasal air pressure transducer (inspiratory effort) by \\> 90% of baseline\n2. The duration of the event lasts at least 10 seconds\n3. At least 90% of the event's duration meets the amplitude reduction criteria for apnea\n\nHypopnea defined as 30% reduction in airflow (or alternative hypopnea sensor) for \u226510 seconds over at least 90% of the event's duration that is associated with a \\>4% fall in oxygen saturation from baseline.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Events/hour", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "48.8", "spread": "19.3"}, {"groupId": "BG001", "value": "43.7", "spread": "16.8"}, {"groupId": "BG002", "value": "46.2", "spread": "18.2"}]}]}]}, {"title": "Central Apnea Index (CAI)", "description": "The number of central apneas per hour of sleep. A central apnea is defined by 4 characteristics:\n\n1. There is a drop in the peak thermal sensor excursion or alternate nasal air pressure transducer (inspiratory effort) by \\> 90% of baseline\n2. The duration of the event lasts at least 10 seconds\n3. At least 90% of the event's duration meets the amplitude reduction criteria for apnea\n4. An apnea associated with absent inspiratory effort throughout the period", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Events/hour", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "30.0", "spread": "18.0"}, {"groupId": "BG001", "value": "26.6", "spread": "16.1"}, {"groupId": "BG002", "value": "28.2", "spread": "17.1"}]}]}]}, {"title": "Arousal Index (ArI)", "description": "The number of arousals per hour of sleep. During sleep stages N1, N2, N3 or rapid eye movement (REM), an abrupt shift of electroencephalogram frequency including alpha, theta and/or frequencies greater than 16 Hz that last at least 3 seconds, with at least 10 seconds of stable sleep preceding the change is an arousal.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Events/hour", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "45.5", "spread": "17.9"}, {"groupId": "BG001", "value": "43.6", "spread": "19.1"}, {"groupId": "BG002", "value": "44.6", "spread": "18.5"}]}]}]}, {"title": "Rapid Eye Movement Sleep (REM)", "description": "REM is a sleep stage. The percentage of sleep in REM is a measure of sleep quality.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "10.4", "spread": "7.2"}, {"groupId": "BG001", "value": "11.8", "spread": "7.1"}, {"groupId": "BG002", "value": "11.1", "spread": "7.1"}]}]}]}, {"title": "Oxygen Desaturation Index (ODI4)", "description": "Number of times per hour of sleep that the blood's oxygen level drops by \u22654%.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Events/hour", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "43.2", "spread": "21.7"}, {"groupId": "BG001", "value": "37.5", "spread": "17.5"}, {"groupId": "BG002", "value": "40.2", "spread": "19.8"}]}]}]}, {"title": "Obstructive Apnea Index", "description": "The number of obstructive apneas per hour of sleep. An obstructive apnea is defined by 4 characteristics:\n\n1. There is a drop in the peak thermal sensor excursion or alternate nasal air pressure transducer (inspiratory effort) by \\> 90% of baseline\n2. The duration of the event lasts at least 10 seconds\n3. At least 90% of the event's duration meets the amplitude reduction criteria for apnea\n4. An apnea associated with continued or increased inspiratory effort throughout the period", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Events/hour", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "2.6", "spread": "3.2"}, {"groupId": "BG001", "value": "2.3", "spread": "2.7"}, {"groupId": "BG002", "value": "2.4", "spread": "3.0"}]}]}]}, {"title": "Epworth Sleepiness Scale (ESS)", "description": "The ESS is an assessment to measure a subject's general level of daytime sleepiness. Scores can range from 0-24, with higher scores indicating higher level of daytime sleepiness.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "units on a scale", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "10.2", "spread": "5.2"}, {"groupId": "BG001", "value": "9.5", "spread": "5.8"}, {"groupId": "BG002", "value": "9.8", "spread": "5.5"}]}]}]}, {"title": "Body mass index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "30.8", "spread": "5.3"}, {"groupId": "BG001", "value": "31.3", "spread": "6.6"}, {"groupId": "BG002", "value": "31.1", "spread": "6.0"}]}]}]}, {"title": "Hypertension", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "53"}, {"groupId": "BG001", "value": "60"}, {"groupId": "BG002", "value": "113"}]}]}]}, {"title": "Heart failure", "description": "Defined as New York Heart Association (NYHA) Functional Class \u2265 I", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "48"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "96"}]}]}]}, {"title": "Left ventricular ejection fraction", "description": "Available for N=71 Treatment and N=75 Control participants.", "populationDescription": "Ejection fraction data not available on all subjects", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "71"}, {"groupId": "BG001", "value": "75"}, {"groupId": "BG002", "value": "146"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "39.7", "spread": "12.1"}, {"groupId": "BG001", "value": "39.4", "spread": "12.2"}, {"groupId": "BG002", "value": "39.6", "spread": "12.1"}]}]}]}, {"title": "Atrial fibrillation", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "64"}]}]}]}, {"title": "Stroke", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}]}]}]}, {"title": "Coronary artery disease", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "40"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "84"}]}]}]}, {"title": "Concomitant implantable device delivering therapy", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "73"}, {"groupId": "BG001", "value": "78"}, {"groupId": "BG002", "value": "151"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "64"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "The Proportion of Participants Experiencing a Reduction in Apnea-hypopnea Index (AHI)", "description": "Comparison of the proportion of subjects in the Treatment group achieving a 50% or greater reduction in AHI from baseline to 6 months compared to the Control group.", "populationDescription": "The population analyzed included all randomized participants who had a 6 month assessment. In addition, Treatment group subjects who did not have a 6 month assessment for reasons related to implant, device or delivered therapy were included as not achieving the endpoint.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Treatment Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy and remed\u0113 System therapy."}, {"id": "OG001", "title": "Control Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy alone (remed\u0113 System inactive through 6 months)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "68"}, {"groupId": "OG001", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "1-sided. p\\<0.025 considered significant.", "statisticalMethod": "Fisher Exact", "paramType": "Risk Difference (RD)", "paramValue": "41", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "25", "ciUpperLimit": "54", "estimateComment": "Risk difference = Treatment - Control"}]}, {"type": "PRIMARY", "title": "Freedom From Related Serious Adverse Events Within 12 Months", "description": "Freedom from serious adverse events (SAEs) associated with the implant procedure, the remede System, or the delivered therapy at 12 months post therapy initiation visit.", "populationDescription": "Intent-to-treat. The study protocol pre-specified that randomized groups be combined to assess freedom from related serious adverse events within 12 months.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "12 months", "groups": [{"id": "OG000", "title": "Pooled Group", "description": "All randomized participants pooled. All subjects were implanted with the remed\u0113 System device and received optimal medical therapy. The Treatment group had received 12 months active therapy and Control had received 6 months active therapy."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "151"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "138"}]}]}]}, {"type": "SECONDARY", "title": "Central Apnea Index (CAI) Change From Baseline at 6 Months", "description": "Change in CAI = Month 6 index - Baseline index. The central apnea index is a measurement used to indicate the severity of central sleep apnea. It is represented by the number of central apnea events per hour of sleep.", "populationDescription": "Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to \"off\" at the 6-month visit, did not have 6-month polysomnogram (PSG) results or had unsuccessful implant attempt.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/hour", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Treatment Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy and remed\u0113 System therapy."}, {"id": "OG001", "title": "Control Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy alone (remed\u0113 System inactive through 6 months)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-25.7", "lowerLimit": "-30.5", "upperLimit": "-21.0"}, {"groupId": "OG001", "value": "-2.9", "lowerLimit": "-7.0", "upperLimit": "1.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "1-sided. Secondary endpoints hierarchically tested with p\\<0.025 considered significant.", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Net)", "paramValue": "-22.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-29.0", "ciUpperLimit": "-16.6", "estimateComment": "Mean difference = Treatment - Control"}]}, {"type": "SECONDARY", "title": "Apnea-Hypopnea Index (AHI) Change From Baseline at 6 Months", "description": "Change in AHI = Month 6 index - Baseline index. The Apnea-Hypopnea Index is a measurement used to indicate the severity of sleep apnea. It is represented by the number of apnea and hypopnea events per hour of sleep.", "populationDescription": "Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to \"off\" at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/hour", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Treatment Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy and remed\u0113 System therapy."}, {"id": "OG001", "title": "Control Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy alone (remed\u0113 System inactive through 6 months)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-23.9", "lowerLimit": "-28.8", "upperLimit": "-19.0"}, {"groupId": "OG001", "value": "1.1", "lowerLimit": "-3.0", "upperLimit": "5.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Secondary endpoints hierarchically tested with p\\<0.025 considered significant.", "statisticalMethod": "t-test, 1 sided", "paramType": "Mean Difference (Net)", "paramValue": "-25.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-31.2", "ciUpperLimit": "-18.7", "estimateComment": "Mean difference = Treatment - Control"}]}, {"type": "SECONDARY", "title": "Arousal Index (ArI) Change From Baseline at 6 Months", "description": "Change in ArI = Month 6 index - Baseline index. The Arousal Index is a measurement used to indicate the number of times per hour of sleep that sleep is disrupted.", "populationDescription": "Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to \"off\" at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/hour", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Treatment Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy and remed\u0113 System therapy."}, {"id": "OG001", "title": "Control Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy alone (remed\u0113 System inactive through 6 months)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-20.2", "lowerLimit": "-25.2", "upperLimit": "-15.2"}, {"groupId": "OG001", "value": "-5.0", "lowerLimit": "-9.2", "upperLimit": "-0.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Secondary endpoints hierarchically tested with p\\<0.025 considered significant.", "statisticalMethod": "t-test, 1 sided", "paramType": "Mean Difference (Net)", "paramValue": "-15.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-21.6", "ciUpperLimit": "-8.7", "estimateComment": "Mean difference = Treatment - Control"}]}, {"type": "SECONDARY", "title": "Rapid Eye Movement (REM) Sleep Change From Baseline at 6 Months", "description": "Change in REM = Month 6 percentage - Baseline percentage. Rapid Eye Movement (REM) is a sleep stage. A higher percentage of sleep in REM is a measure of better sleep quality.", "populationDescription": "Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to \"off\" at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of sleep", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Treatment Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy and remed\u0113 System therapy."}, {"id": "OG001", "title": "Control Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy alone (remed\u0113 System inactive through 6 months)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.8", "lowerLimit": "-0.3", "upperLimit": "4.0"}, {"groupId": "OG001", "value": "-0.6", "lowerLimit": "-2.4", "upperLimit": "1.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.0244", "pValueComment": "1-sided. Secondary endpoints hierarchically tested with p\\<0.025 considered significant.", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Net)", "paramValue": "2.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.4", "ciUpperLimit": "5.1", "estimateComment": "Mean difference = Treatment - Control"}]}, {"type": "SECONDARY", "title": "The Proportion of Participants Experiencing a Marked or Moderate Improvement in Patient Global Assessment at 6 Months", "description": "The proportion of subjects with a \"moderate\" or \"marked\" improvement in the Patient Global Assessment from baseline to the 6 month visit", "populationDescription": "Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to \"off\" at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt. Note: 1 Control subject did not provide a response and is excluded from analysis.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Treatment Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy and remed\u0113 System therapy."}, {"id": "OG001", "title": "Control Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy alone (remed\u0113 System inactive through 6 months)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "72"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "1-sided. Secondary endpoints hierarchically tested with p\\<0.025 considered significant.", "statisticalMethod": "Fisher Exact", "paramType": "Risk Difference (RD)", "paramValue": "55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "40", "ciUpperLimit": "68", "estimateComment": "Risk difference = Treatment - Control"}]}, {"type": "SECONDARY", "title": "Oxygen Desaturation Index 4% (ODI4) Change From Baseline at 6 Months", "description": "Change in ODI4 = Month 6 index - Baseline index. The Oxygen Desaturation Index 4% is a measurement of the number of times per hour of sleep that the blood's oxygen level drops \u22654%.", "populationDescription": "Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to \"off\" at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Events/hour", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Treatment Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy and remed\u0113 System therapy."}, {"id": "OG001", "title": "Control Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy alone (remed\u0113 System inactive through 6 months)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-19.1", "lowerLimit": "-23.9", "upperLimit": "-14.3"}, {"groupId": "OG001", "value": "3.6", "lowerLimit": "-0.5", "upperLimit": "7.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "Secondary endpoints hierarchically tested with p\\<0.025 considered significant.", "statisticalMethod": "t-test, 1 sided", "paramType": "Mean Difference (Net)", "paramValue": "-22.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.9", "ciUpperLimit": "-16.5", "estimateComment": "Mean difference = Treatment - Control"}]}, {"type": "SECONDARY", "title": "Epworth Sleepiness Scale (ESS) Change From Baseline at 6 Months", "description": "Change in ESS = Month 6 score - Baseline score. The ESS is an assessment to measure a subject's general level of daytime sleepiness. Scores can range from 0-24, with higher scores indicating higher level of daytime sleepiness.", "populationDescription": "Per protocol: excludes patients who did not meet major entry criteria, had therapy programmed to \"off\" at the 6-month visit, did not have 6-month PSG results or had unsuccessful implant attempt.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "6 months", "groups": [{"id": "OG000", "title": "Treatment Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy and remed\u0113 System therapy."}, {"id": "OG001", "title": "Control Group", "description": "Subjects implanted with the remed\u0113 System device who receive optimal medical therapy alone (remed\u0113 System inactive through 6 months)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "58"}, {"groupId": "OG001", "value": "73"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.6", "lowerLimit": "-5.1", "upperLimit": "-2.1"}, {"groupId": "OG001", "value": "0.1", "lowerLimit": "-0.9", "upperLimit": "1.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.0001", "pValueComment": "1-sided. Secondary endpoints hierarchically tested with p\\<0.025 considered significant.", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Net)", "paramValue": "-3.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.5", "ciUpperLimit": "-2.0", "estimateComment": "Mean difference = Treatment - Control"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Implant through 12 Months post therapy initiation visit window", "eventGroups": [{"id": "EG000", "title": "Pooled Group", "description": "The study protocol pre-specified that randomized groups be combined to assess safety. All subjects were implanted with the remed\u0113 System device and received optimal medical therapy. The Treatment group had received 12 months active therapy and Control had received 6 months active therapy.", "deathsNumAffected": 7, "deathsNumAtRisk": 151, "seriousNumAffected": 74, "seriousNumAtRisk": 151, "otherNumAffected": 53, "otherNumAtRisk": 151}], "seriousEvents": [{"term": "ANEMIA", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "HEART FAILURE", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 151}]}, {"term": "SUSTAINED VENTRICULAR TACHY ARRHYTHMIA", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 151}]}, {"term": "ATRIAL FIBRILLATION", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 151}]}, {"term": "AORTIC VALVE DISEASE", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 151}]}, {"term": "CORONARY ARTERY DISEASE", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 151}]}, {"term": "CHEST PAIN - CARDIAC", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "COMPLICATION OF HEART FAILURE THERAPY", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "ACUTE CORONARY SYNDROME", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ATRIAL FLUTTER", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "COMPLICATION OF CARDIAC SURGERY", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "INAPPROPRIATE ICD SHOCK", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "MITRAL VALVE DISEASE", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "PERICARDIAL EFFUSION", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "RIGHT HEART PERFORATION", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "SICK SINUS SYNDROME", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "SUDDEN DEATH", "organSystem": "Cardiac disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "DIABETIC KETOACIDOSIS", "organSystem": "Endocrine disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "DIABETIC TOE", "organSystem": "Endocrine disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "GASTROESOPHAGEAL REFLUX DISEASE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "COLONIC PERFORATION", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "DIVERTICULITIS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "GASTROINTESTINAL BLEED SECONDARY TO WARFARIN", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "GASTROPARESIS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "INGUINAL HERNIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "PERFORATED BOWEL", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "IMPENDING POCKET EROSION", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 151}]}, {"term": "IMPLANT SITE INFECTION", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "NON-CARDIAC CHEST PAIN", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "STIMULATION LEAD DISLODGEMENT (REMEDE SYSTEM)", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "The stimulation lead pulled out of the target vessel and required the lead to be replaced in order to deliver therapy", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "ABDOMINAL DISCOMFORT", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ALTERED MENTAL STATUS", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "CONCOMITANT DEVICE INTERACTION", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "DEGENERATIVE JOINT DISEASE", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ELECTIVE EXPLANT OF REMEDE SYSTEM", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "EXTRA-RESPIRATORY STIMULATION", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Discomfort of feeling delivered therapy in areas remote from the diaphragm", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "FLU LIKE SYMPTOMS", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ICD LEAD FAILURE", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "IMPLANT SITE HEMATOMA", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "SINUS INFECTION", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "STIMULATION LEAD COMPONENT FAILURE (REMEDE SYSTEM)", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "STIMULATION LEAD DISPLACEMENT (REMEDE SYSTEM)", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "The stimulation lead remained in the target vessel but electrode position did not allow for effective therapy delivery", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "SEPSIS", "organSystem": "Infections and infestations", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 151}]}, {"term": "PNEUMONIA", "organSystem": "Infections and infestations", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "BLADDER INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "BRONCHIAL INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "CELLULITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "DIABETIC FOOT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ENDOCARDITIS INFECTIVE", "organSystem": "Infections and infestations", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ICD IMPLANT SITE INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "LEG CELLULITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 151}]}, {"term": "AORTIC INJURY", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "INTRAOPERATIVE NEUROLOGICAL INJURY", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ELEVATED TRANSAMINASE", "organSystem": "Investigations", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "DEHYDRATION", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "HYPERGLYCEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "HYPOGLYCEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ARTHRITIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "BICEP TENDON TEAR", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "MENISCUS TEAR", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "RHABDOMYOLOSIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ADENOCARCINOMA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "LUNG CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "MYELODYSPLASTIC SYNDROME", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "PROSTATE CARCINOMA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "STROKE", "organSystem": "Nervous system disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "AMNESIA", "organSystem": "Nervous system disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ENCEPHALOPATHY", "organSystem": "Nervous system disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "MEMORY IMPAIRMENT", "organSystem": "Nervous system disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "SEIZURE", "organSystem": "Nervous system disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "TRANSIENT ISCHEMIC ATTACKS", "organSystem": "Nervous system disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ACUTE KIDNEY INJURY", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "URINARY TRACT STENOSIS", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "DYSPNEA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "PULMONARY EDEMA", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "RESPIRATORY FAILURE", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "CRT-D IMPLANT", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "CYCLOPHOTOCOAGULATION", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "DRUG ELUTING STENT", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ICD GENERATOR AND RV LEAD REPLACEMENT", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "ICD IMPLANT", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "LEFT SUBTALAR JOINT ARTHRODESIS, HARDWARE REMOVAL AND BONE GRAFTING", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "TOOTH EXTRACTION", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}, {"term": "HYPOTENSION", "organSystem": "Vascular disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 151}]}, {"term": "PULMONARY EMBOLISM", "organSystem": "Vascular disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}]}], "otherEvents": [{"term": "DIAPHRAGMATIC STIMULATION DISCOMFORT", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Discomfort in the abdominal area due to remede System delivered therapy", "stats": [{"groupId": "EG000", "numAffected": 38, "numAtRisk": 151}]}, {"term": "EXTRA-RESPIRATORY STIMULATION", "organSystem": "General disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Discomfort of feeling delivered therapy in areas remote from the diaphragm", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 151}]}, {"term": "PAIN IN EXTREMITY", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "Modified CTCAE v4.03", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 151}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Linda Nelson, VP Clinical Affairs", "organization": "Respicardia, Inc.", "email": "lnelson@respicardia.com", "phone": "952-540-4479"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000012891", "term": "Sleep Apnea Syndromes"}, {"id": "D000020182", "term": "Sleep Apnea, Central"}], "ancestors": [{"id": "D000001049", "term": "Apnea"}, {"id": "D000012120", "term": "Respiration Disorders"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000020919", "term": "Sleep Disorders, Intrinsic"}, {"id": "D000020920", "term": "Dyssomnias"}, {"id": "D000012893", "term": "Sleep Wake Disorders"}, {"id": "D000009422", "term": "Nervous System Diseases"}], "browseLeaves": [{"id": "M4361", "name": "Apnea", "relevance": "LOW"}, {"id": "M15694", "name": "Sleep Apnea Syndromes", "asFound": "Sleep Disordered Breathing", "relevance": "HIGH"}, {"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M9421", "name": "Heart Failure", "relevance": "LOW"}, {"id": "M22011", "name": "Sleep Apnea, Central", "asFound": "Sleep Apnea, Central", "relevance": "HIGH"}, {"id": "M16355", "name": "Syndrome", "relevance": "LOW"}, {"id": "M14957", "name": "Respiration Disorders", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M22242", "name": "Parasomnias", "relevance": "LOW"}, {"id": "M22654", "name": "Sleep Disorders, Intrinsic", "relevance": "LOW"}, {"id": "M22655", "name": "Dyssomnias", "relevance": "LOW"}, {"id": "M15696", "name": "Sleep Wake Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC10", "name": "Nervous System Diseases"}, {"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}]}}, "hasResults": true}